{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T16:58:40Z","timestamp":1777913920634,"version":"3.51.4"},"reference-count":44,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2014,8,13]],"date-time":"2014-08-13T00:00:00Z","timestamp":1407888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Toxicol Pathol"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:p>Administration of lersivirine, a nonnucleotide reverse transcriptase inhibitor, daily by oral gavage to Sprague-Dawley rats for up to 2 yr was associated with decreased survival, decreased body weights, and an increase in neoplasms and related proliferative lesions in the liver, thyroid, kidney, and urinary bladder. Thyroid follicular adenoma and carcinoma, the associated thyroid follicular hypertrophy\/hyperplasia, hepatocellular adenoma\/adenocarcinoma, altered cell foci, and hepatocellular hypertrophy were consistent with lersivirine-related induction of hepatic microsomal enzymes. Renal tubular adenoma and renal tubular hyperplasia were attributed to the lersivirine-related exacerbation of chronic progressive nephropathy (CPN), while urinary bladder hyperplasia and transitional cell carcinoma in the renal pelvis and urinary bladder were attributed to urinary calculi. Renal tubular neoplasms associated with increased incidence and severity of CPN, neoplasms of transitional epithelium attributed to crystalluria, and thyroid follicular and hepatocellular neoplasms related to hepatic enzyme induction have low relevance for human risk assessment.<\/jats:p>","DOI":"10.1177\/0192623314544381","type":"journal-article","created":{"date-parts":[[2014,8,13]],"date-time":"2014-08-13T22:04:53Z","timestamp":1407967493000},"page":"354-365","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Two-year Carcinogenicity Study in Rats with a Nonnucleoside Reverse Transcriptase Inhibitor"],"prefix":"10.1177","volume":"43","author":[{"given":"Prashant R.","family":"Nambiar","sequence":"first","affiliation":[{"name":"Pfizer Inc., Groton, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Morton","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Cambridge, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leland Wayne","family":"Dochterman","sequence":"additional","affiliation":[{"name":"Covance Laboratories Inc., Madison, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Houle","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Groton, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Thomford","sequence":"additional","affiliation":[{"name":"Covance Laboratories Inc., Madison, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwendolyn","family":"Fate","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Groton, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven A.","family":"Bailey","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Andover, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory L.","family":"Finch","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Groton, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2014,8,13]]},"reference":[{"key":"bibr1-0192623314544381","first-page":"226","volume":"8","author":"Berruet N.","year":"2005","journal-title":"J Pharm Pharmaceut Sci"},{"key":"bibr2-0192623314544381","unstructured":"Boorman G. A., Eustis S. L., Elwell M. R., Montgomery C. A., MacKenzie W. F. (1990). Pathology of the fischer rat, reference and atlas, pp. 113\u201324. Academic Press, San Diego, CA."},{"key":"bibr3-0192623314544381","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01455-09"},{"key":"bibr4-0192623314544381","doi-asserted-by":"publisher","DOI":"10.1080\/01926230601072327"},{"key":"bibr5-0192623314544381","unstructured":"EMA (European Medicines Agency). (2007). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003255.pdf."},{"key":"bibr5a-0192623314544381","unstructured":"EMA (European Medicines Agency). (2013a). Sustiva summary of product characteristics. Accessed July 12, 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000249\/WC500058311.pdf."},{"key":"bibr6-0192623314544381","unstructured":"EMA (European Medicines Agency). (2013b). Viramune summary of product characteristics. Accessed July 12, 2013. http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000183\/WC500051481.pdf."},{"key":"bibr7-0192623314544381","unstructured":"EMA (European Medicines Agency). (2013c). Intelence summary of product characteristics. Accessed July 12, 2013. http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000900\/WC500034180.pdf."},{"key":"bibr8-0192623314544381","unstructured":"FDA (Food and Drug Administration). (2001). Guidance for industry: Statistical aspects of the design, analysis, and interpretation of chronic rodent carcinogenicity studies of pharmaceuticals (DRAFT). Accessed July 12, 2013. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm079272.pdf."},{"key":"bibr9-0192623314544381","unstructured":"FDA (Food and Drug Administration). (2003). Sustiva product label. Accessed July 12, 2013. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/20972slr021,21360slr005_sustiva_lbl.pdf."},{"key":"bibr10-0192623314544381","unstructured":"FDA (Food and Drug Administration). (2011). Edurant pharmacology review, summary basis of approval. Accessed July 12, 2013. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/202022Orig1s000PharmR.pdf."},{"key":"bibr11-0192623314544381","unstructured":"FDA (Food and Drug Administration). (2012a). Viramune product label. Accessed July 12, 2013. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020636s042,020933s033lbl.pdf."},{"key":"bibr12-0192623314544381","unstructured":"FDA (Food and Drug Administration). (2012b). Rescriptor product label. Accessed July 12, 2013. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020705s018lbl.pdf."},{"key":"bibr13-0192623314544381","unstructured":"FDA (Food and Drug Administration). (2013a). Intelence product label. Accessed July 12, 2013. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/022187s011s012s014lbl.pdf."},{"key":"bibr14-0192623314544381","unstructured":"FDA (Food and Drug Administration). (2013b). Edurant product label. Accessed July 12, 2013. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/202022s005lbl.pdf."},{"key":"bibr15-0192623314544381","doi-asserted-by":"publisher","DOI":"10.1177\/0192623312438736"},{"key":"bibr16-0192623314544381","unstructured":"Giknis M. L. A., Clifford C. B. (2004). Compilation of spontaneous neoplastic lesions and survival in Crl: CD\u00ae rats from control groups. Charles River Laboratories. Accessed July 12, 2013. http:\/\/www.criver.com\/SiteCollectionDocuments\/rm_rm_r_lesions_survival_crlcd_sd_rats.pdf."},{"key":"bibr17-0192623314544381","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2008.09.002"},{"key":"bibr18-0192623314544381","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-53856-7.00009-9"},{"key":"bibr19-0192623314544381","doi-asserted-by":"publisher","DOI":"10.1177\/0192623311431948"},{"key":"bibr20-0192623314544381","doi-asserted-by":"publisher","DOI":"10.1080\/10408440802368642"},{"key":"bibr21-0192623314544381","doi-asserted-by":"publisher","DOI":"10.1080\/01926230490422574"},{"key":"bibr22-0192623314544381","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-0590(83)80148-1"},{"key":"bibr23-0192623314544381","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfj001"},{"key":"bibr24-0192623314544381","doi-asserted-by":"publisher","DOI":"10.1006\/taap.1999.8752"},{"key":"bibr25-0192623314544381","doi-asserted-by":"publisher","DOI":"10.1177\/0192623313503516"},{"key":"bibr26-0192623314544381","doi-asserted-by":"publisher","DOI":"10.1517\/14656560903176446"},{"key":"bibr27-0192623314544381","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.742506"},{"key":"bibr28-0192623314544381","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"bibr29-0192623314544381","doi-asserted-by":"publisher","DOI":"10.1177\/019262338901700206"},{"key":"bibr30-0192623314544381","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4274(92)90213-4"},{"key":"bibr31-0192623314544381","first-page":"283","volume":"76","author":"McConnell E. E.","year":"1986","journal-title":"J Natl Cancer Inst"},{"key":"bibr35-0192623314544381","first-page":"807","author":"Morton D.","year":"2013","journal-title":"Toxicologic Pathology vol II"},{"key":"bibr32-0192623314544381","unstructured":"NTP (National Toxicology Program). (1983). Technical report on the carcinogenesis bioassay of melamine (CAS No. 108-78-1). National Institutes of Health Publication No. 83-2501. Accessed August 10, 2013. http:\/\/ntp.niehs.nih.gov\/ntp\/htdocs\/LT_rpts\/tr245.pdf."},{"key":"bibr33-0192623314544381","first-page":"311","volume-title":"Long-term and Short-term Screening Assays for Carcinogens: A Critical Appraisal","author":"Peto R.","year":"1980"},{"key":"bibr34-0192623314544381","unstructured":"SAS (Statistical Analysis System). (2002-2008). Version 9.2. SAS Institute Inc. Cary, NC, USA."},{"key":"bibr36-0192623314544381","doi-asserted-by":"publisher","DOI":"10.2165\/10895940-000000000-00000"},{"key":"bibr37-0192623314544381","doi-asserted-by":"publisher","DOI":"10.1293\/tox.21.199"},{"key":"bibr38-0192623314544381","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfp256"},{"key":"bibr39-0192623314544381","doi-asserted-by":"publisher","DOI":"10.1016\/0010-4809(77)90006-4"},{"key":"bibr40-0192623314544381","doi-asserted-by":"publisher","DOI":"10.1080\/00498250902903079"},{"key":"bibr41-0192623314544381","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/34.1-2.28"},{"key":"bibr42-0192623314544381","doi-asserted-by":"publisher","DOI":"10.1097\/01.mjt.0000209673.01885.b0"},{"key":"bibr43-0192623314544381","doi-asserted-by":"publisher","DOI":"10.1177\/0192623311406934"}],"container-title":["Toxicologic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0192623314544381","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0192623314544381","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0192623314544381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T16:36:29Z","timestamp":1777653389000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0192623314544381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,13]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1177\/0192623314544381"],"URL":"https:\/\/doi.org\/10.1177\/0192623314544381","relation":{},"ISSN":["0192-6233","1533-1601"],"issn-type":[{"value":"0192-6233","type":"print"},{"value":"1533-1601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,13]]}}}